Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement

por Eichler, Hans-Georg, Kossmeier, Michael, Zeitlinger, Markus, Schwarzer-Daum, Brigitte
Publicado 2023

Precision Reimbursement for Precision Medicine: Using Real‐World Evidence to Evolve From Trial‐and‐Project to Track‐and‐Pay to Learn‐and‐Predict

por Eichler, Hans‐Georg, Trusheim, Mark, Schwarzer‐Daum, Brigitte, Larholt, Kay, Zeitlinger, Markus, Brunninger, Martin, Sherman, Michael, Strutton, David, Hirsch, Gigi
Publicado 2021

Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation

por Eichler, Hans‐Georg, Koenig, Franz, Arlett, Peter, Enzmann, Harald, Humphreys, Anthony, Pétavy, Frank, Schwarzer‐Daum, Brigitte, Sepodes, Bruno, Vamvakas, Spiros, Rasi, Guido
Publicado 2019

Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth

por Eichler, Hans‐Georg, Pignatti, Francesco, Schwarzer‐Daum, Brigitte, Hidalgo‐Simon, Ana, Eichler, Irmgard, Arlett, Peter, Humphreys, Anthony, Vamvakas, Spiros, Brun, Nikolai, Rasi, Guido
Publicado 2020

Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities

por Dal-Ré, Rafael, Bekker, Linda-Gail, Gluud, Christian, Holm, Søren, Jha, Vivekanand, Poland, Gregory A, Rosendaal, Frits R, Schwarzer-Daum, Brigitte, Sevene, Esperança, Tinto, Halidou, Voo, Teck Chuan, Sreeharan, Nadarajah
Publicado 2021

Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit–The EU Regulator's Perspective

por Sheean, Maria E., Naumann-Winter, Frauke, Capovilla, Giuseppe, Kalland, Maria Elisabeth, Malikova, Eva, Mariz, Segundo, Matusevicius, Darius, Nistico, Robert, Schwarzer-Daum, Brigitte, Tsigkos, Stelios, Tzogani, Kyriaki, Larsson, Kristina, Magrelli, Armando, Stoyanova-Beninska, Violeta
Publicado 2021